Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
2010
DNA Damage–Specific Control of Cell Death by Cryptochrome in p53-Mutant Ras–Transformed Cells
2012 StandoutNobel
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Triple-Negative Breast Cancer
2010 Standout
Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA
2009
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
2010
Efficacy and safety of cefepime: a systematic review and meta-analysis
2007
Pancreatic cancer
2004 Standout
MONOTHERAPY WITH PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIA IN PEDIATRIC CANCER PATIENTS: A Randomized Comparison
2006
Breast cancer
2016 Standout
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Ovarian cancer
2014 Standout
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study
2005
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Nanocarriers for delivery of platinum anticancer drugs
2013
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data
2007
Metagenomic biomarker discovery and explanation
2011 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Capecitabine: A review
2005
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Overview of the clinical efficacy of investigational anticancer drugs
2003
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998
Tumour-inhibiting platinum complexes—state of the art and future perspectives
2003
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies
2006
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Ongoing and unsaid on oxaliplatin: the hope
1998
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
1998
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Treatment of febrile neutropenic patients with cancer who require hospitalization
2003
Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia
2001
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
2009 Standout
Recent insights into platinum drug resistance in cancer
1998
Preservation of Fertility in Patients with Cancer
2009 Standout
Antitumour activity of oxaliplatin in neuroblastoma cell lines
1999
Prediction of Gram-Negative Bacteremia in Patients with Cancer and Febrile Neutropenia by Means of Interleukin-8 Levels in Serum: Targeting Empirical Monotherapy versus Combination Therapy
2001
Randomized, Double-Blind, Multicenter Trial Comparing Clinafloxacin with Imipenem as Empirical Monotherapy for Febrile Granulocytopenic Patients
2001
Pancreatic cancer
2011 Standout
Chaperone-mediated Autophagy Targets Hypoxia-inducible Factor-1α (HIF-1α) for Lysosomal Degradation
2013 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
2005
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Second-Line Treatment of Ovarian Cancer
2000
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
2000
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Breast Cancer Treatment
2019 Standout
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
2008
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Reply to Paul et al
2009
Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT
2007
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Consenso Manejo racional del paciente con cáncer, neutropenia y fiebre: Rational approach towards the patient with cancer, fever and neutropenia
2005
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Advances in Copper Complexes as Anticancer Agents
2013 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
2008
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
Works of H. Curé being referenced
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
2003
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate
2003
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma
1998
Clinical and pathological response to primary chemotherapy in operable breast cancer
1997
High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)
2001
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.
1997
A phase II trial of ZD0473 in platinum-pretreated ovarian cancer
2002
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
2003
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
1996
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
2002
5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma. A randomized study
1996
Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project.
2011
ZD0473 phase II monotherapy trial in second-line ovarian cancer
2001
Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and l-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal Cancer
2002
Primary Chemotherapy in Breast Cancer
1998
Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer.
2001
High-dose chemotherapy and autologous stem cell transplantation in advanced epithelial ovarian cancer.
1996
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
1997
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy
2002
Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)
1998